Table 1

Baseline characteristics of patients with and without indications for a statin who were/were not taking a statin

Variable (unit)*Patients with no indication for a statinPatients with indication for a statinP valuePatients with indication for a statin and were on a StatinPatients with indication for a statin and were not on a StatinP value
Demographic data
No of patients (n)565267129138
Age (year)38.0 (31.00–44.00)51.0 (46.0–57.0)<0.00151.00 (46.00–58.00)51.00 (46.00–56.00)0.575
Sex, n (% male)407 (72.10)197 (73.78)0.96693 (72.30)103 (74.20)0.797
BMI (kg/m2)30.81 (28.16–34.81)31.93 (28.25–35.43)0.11532.43 (28.70–35.18)31.39 (27.50–35.44)0.520
Liver function test
AST (U/L)36.00 (28.00–48.25)35.5 (28.0–48.0)0.52037.00 (28.00–49.00)35.00 (27.00–45.00)0.339
ALT (U/L)65.00 (46.00–92.00)59.0 (40.00–78.75)0.15560.00 (44.00–83.00)58.00 (39.00–77.00)0.503
Total bilirubin (umol/L)11(9-16)11(9-15)0.86511 (9–15)11(9-15)0.805
Albumin (g/L)46(44-47)45.00 (43.00–47.00)0.13945.00 (43.00–47.00)45(43-47)0.619
GGT (U/L)51.00 (32.00–88.00)58.0 (36.0–114)0.00466.0 (36.0–141.0)58.00 (38.00–97.50)0.240
Platelets (109 /L)243.0 (207.0–282.8)223.0 (192.0–267.0)0.001221.5 (188.2–262.0)223.0 (192.0–270.00)0.534
Diabetes profile
HBA1C (%)5.50 (5.30–5.80)6.00 (5.30–7.1)<0.0016.0 (5.78–6.75)6.00 (5.70–6.70)0.415
Fasting plasma glucose (mmol/L)5.20 (4.90–5.60)6.00 (5.60–6.70)<0.0016.2 (5.45–7.10)5.90 (5.30–7.20)0.187
Diabetic classification
Diabetes (n)40 (7.1%)135 (50.6%)<0.00161 (47.2%)74 (53.6%)0.202
Pre-diabetes (n)249 (44.1%)88 (32.9%)44 (31.1%)44 (31.9%)
Normal (n)276 (48.8%)44 (16.5%)24 (18.6%)20 (14.5%)
Lipid profile
Total cholesterol (mmol/L)5.01 (4.43–5.65)4.62 (3.86–5.46)<0.0014.05 (3.52–4.68)5.24 (4.56–5.92)<0.001
HDL (mmol/L)1.12 (0.97–1.30)1.12 (0.96–1.26)0.9451.11 (0.93–1.32)1.12 (0.99–1.22)0.679
LDL (mmol/L)3.04 (2.57–3.56)2.64 (1.96–3.39)<0.0012.00 (1.64–2.56)3.16 (2.69–3.81)<0.001
Non-HDL cholesterol (mmol/L)3.87 (3.30–4.51)3.55 (2.75–4.36)<0.0012.84 (2.36–3.46)4.13 (3.57–4.75)<0.001
Non-invasive tests
AST/ALT0.57 (0.48–0.70)0.62 (0.52–0.77)0.0010.63 (0.53–0.80)0.67 (0.50–0.77)0.671
AST/√ALT4.50 (3.95–5.32)4.58 (4.02–5.76)0.0684.77 (4.03–5.89)4.49 (4.03–5.63)0.527
FIB-40.69 (0.52–0.93)1.08 (0.80–1.49)<0.0011.14 (0.83–1.51)1.02 (0.80–1.47)0.237
NFS−2.89 (-3.50–-2.22)−1.35 (-2.22–-0.68)<0.001−1.32 (-2.09–-0.58)−1.62 (-2.38–-0.79)0.323
Hepamet0.02 (0.01–0.05)0.10 (0.04–0.21)<0.0010.10 (0.04–0.21)0.1 (0.04–0.21)0.994
VCTE (kPa)5.20 (4.30–6.10)5.80 (4.55–7.35)<0.0015.90 (4.60–7.90)5.45 (4.50–6.80)0.237
Fibrosis prevalence
VCTE ≥850 (9%)54 (20%)32 (25%)22 (16%)
VCTE ≥1031 (5%)40 (15%)21 (16%)19 (14%)
VCTE ≥1217 (3%)27 (10%)17 (13%)10 (7%)
VCTE ≥168 (1%)12 (4%)9 (7%)4 (3%)
  • *P value correspond to univariable. Results present in median (IQR) or in frequencies (%). AST/vALT: ratio of aspartate aminotransferase to the square root of alanine aminotransferase. HDL: high density lipoprotein cholesterol. LDL: low density lipoprotein cholesterol. HBA1c : hemoglobin A1c. GGT: gamma-glutamyl transferase.

  • BMI, body mass index; NFS, NAFLD Fibrosis Score; VCTE, vibration controlled transient elastography.